Item 7.01 Regulation FD Disclosure
The registration statement on Form 10 filed byBiohaven Ltd. with theSecurities and Exchange Commission ("SEC") in connection with the previously announced spin-off byBiohaven Pharmaceutical Holding Company Ltd. ("Biohaven") ofBiohaven Ltd. became effective onSeptember 22, 2022 .Biohaven Ltd. will own the Kv7 ion channel activators, glutamate modulation, myeloperoxidase inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned byBiohaven .Biohaven Ltd. common shares will begin trading today,September 23, 2022 , on a "when-issued" basis on theNew York Stock Exchange under the symbol "BHVN WI" and under "Biohaven Ltd. " "When-issued" trading ofBiohaven Ltd. common shares will continue until the spin-off occurs. The distribution date for the spin-off is expected to be early in the fourth quarter of 2022, subject to the closing conditions noted inBiohaven's Proxy Statement filed with theSEC onAugust 30, 2022 , including receipt of shareholder approval atBiohaven's special meeting of shareholders to be held onSeptember 29, 2022 . The CUSIP number forBiohaven Ltd. common shares will be G1110E 107. The information set forth in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit Number Exhibit Description 104 The cover page of this Current Report on Form 8-K formatted as Inline XBRL. 2
--------------------------------------------------------------------------------
© Edgar Online, source